Current position

Cathie Wood’s CRISPR Therapeutics (CRSP) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

ARK Investment ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2017Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares11.31MHighest verified quarter-end share count
Quarters reported35Verified quarters with shares above zero
What happened?

ARK Investment Management first reported CRISPR Therapeutics in Q3 2017. The reported position was increased and reduced across later filings. ARK Investment Management currently reports 9.46M shares. The latest verified filing showed: Sold 16.4% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 16.4% of the position−1.85M shares · 9.46M shares remained
Filing context

Quarter-end price $54.54 · Estimated holding basis $61.71

Q1 2026
Bought 7.5% more+791.57K shares · 11.31M shares reported after the change
Filing context

Quarter-end price $47.57 · Estimated holding basis $61.71

Q4 2025
Bought 7.5% more+735.08K shares · 10.52M shares reported after the change
Filing context

Quarter-end price $52.44 · Estimated holding basis $62.77

Q3 2025
Sold 3.9% of the position−395.62K shares · 9.79M shares remained
Filing context

Quarter-end price $64.81 · Estimated holding basis $63.55

Q2 2025
Bought 0.2% more+17.19K shares · 10.18M shares reported after the change
Filing context

Quarter-end price $48.64 · Estimated holding basis $63.55

Q1 2025
Bought 13.3% more+1.19M shares · 10.17M shares reported after the change
Filing context

Quarter-end price $34.03 · Estimated holding basis $63.57

Portfolio importance

How important is CRISPR Therapeutics in ARK Investment Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight3.4%Q2 2026
Current rank#6of 190 reported positions
Peak portfolio weight5.1%Q2 2020
Best historical rank#3Q4 2020
At peak importanceQ2 2020
CRSP
5.1%
Largest holding
8.3%
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$56.562026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$54.54Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$61.71Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View CRISPR Therapeutics stock page →

This tracker follows ARK Investment Management’s aggregated Form 13F disclosures. It is not Cathie Wood’s personal brokerage account, and 13F filings do not reveal exact trade dates or execution prices.